Poplar Therapeutics Closes $45 million Series A Extension to Advance Development of Lead Program, PHB-050, A New Class of Anti-IgE Therapy for Multiple Atopic Conditions Extension financing adds new investors, Janus Henderson Investors and RA Capital, with strong renewed participation…
Researchers at the Feinstein Institutes identify noninvasive biomarkers that detect early brain changes in acute liver injury, enabling faster intervention and improved patient outcomes. Scientists at the Feinstein Institutes for Medical Research, the research arm of Northwell Health, have unveiled…
PharmaEssentia Corporation gains regulatory clearance from Japan’s Ministry of Health, Labour and Welfare to add an alternative high-dose dosing schedule for BESREMi, offering a shortened titration period and greater flexibility for patients. PharmaEssentia Corporation , a globally recognized biopharmaceutical innovator…
Pacific Coast Oil Trust Announces Monthly Net Profits Interest Calculations Pacific Coast Oil Trust, a Delaware statutory trust formed by Pacific Coast Energy Company LP (PCEC), is navigating a complex financial landscape as it faces dissolution due to ongoing operational…
Meiji Seika Pharma’s Morcamilast (ME3183) Receives Orphan Medicinal Product Designation from the European Commission for Palmoplantar Pustulosis Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Toshiaki Nagasato) has announced a significant milestone in the development of its…
Nicoya Life Sciences Expands Access to Gold-Standard SPR with Launch of Revo™ Platform Nicoya Life Sciences, Inc., a recognized leader in advanced biophysical characterization technologies for biologics discovery and development, has announced the launch of Revo™, a next-generation, label-free binding…
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for Fibromyalgia Management Axsome Therapeutics, Inc. a biopharmaceutical company pioneering innovative treatments for central nervous system (CNS) disorders, announced today that the first patient has been dosed in the FORWARD Phase…
Sandoz Secures European Commission Approval for Ondibta® (Insulin Glargine), Reinforcing Leadership in Biosimilars and Diabetes Care Sandoz a global leader in affordable medicines, today announced that the European Commission has granted marketing authorization for Ondibta® (insulin glargine), a solution for…
Teva Pharmaceuticals Highlights AJOVY® Efficacy in Pediatric Migraine Following Publication in New England Journal of Medicine Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the New England Journal of Medicine (NEJM)…
Johnson & Johnson Announces Positive Phase 3 Results for TECVAYLI® Monotherapy in Early Relapse Multiple Myeloma Johnson & Johnson a global leader in oncology innovation and multiple myeloma treatment, has announced encouraging topline results from the Phase 3 MajesTEC-9 clinical…